{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02223897",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2014006"
      },
      "Organization": {
        "OrgFullName": "Third Affiliated Hospital, Sun Yat-Sen University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions",
      "OfficialTitle": "Umbilical Cord Mesenchymal Stem Cells Transplantation for Treatment of Patients With Ischemic-type Biliary Lesions After Liver Transplantation"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2014",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2017",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2018",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 21, 2014",
      "StudyFirstSubmitQCDate": "August 21, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 22, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "August 21, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "August 22, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yang Yang",
        "ResponsiblePartyInvestigatorTitle": "Department of Transplantation",
        "ResponsiblePartyInvestigatorAffiliation": "Third Affiliated Hospital, Sun Yat-Sen University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Yang Yang",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Ischemic-type biliary lesions (ITBLs) are a major cause of graft loss and mortality after orthotopic liver transplantation (OLT). For now, there are still lacking effective treatment for ITBLs. The purpose of this study is to confirm whether human umbilical cord mesenchymal stem cells are effective in the treatment,or prevention of Ischemic-type Biliary Lesions after liver transplantation.",
      "DetailedDescription": "Advances in organ preservation techniques, immunosuppressive regimens, and surgical techniques have resulted in reduced rates of infection, acute rejection and vascular complications after orthotopic liver transplantation (OLT). However, ischemic-type biliary lesions (ITBLs) are still one of the most serious complications after OLT, with a usual reported incidence of 5-15%, and an incidence of up to 26% in some studies. 46% patients with ITBLs require re-transplantation after 2 years of OLT.\n\nMesenchymal stem cells (MSCs),a kind of pluripotent stem cells,can differentiate into vascular endothelial cells, which participate in angiogenesis in ischemic tissue. MSCs can also stimulate the proliferation and migration of mature endothelial cells via paracrine.Furthermore, MSCs secret a variety of cytokines and growth factors, such as vascular endothelial growth factor, human basic fibroblast growth factor, hepatocyte growth factor, interleukin-1 and interleukin-8, etc., which also induce angiogenesis.\n\nParticipants in the study will be randomly assigned to one of two treatment arms:\n\nArm A: Participants will receive 6 months of standard regular treatment for ITBLs plus huc-MSCs treatment.\nArm B: Participants will receive 6 months of standard regular treatment for ITBLs plus placebo.\n\nhuc-MSCs will be prepared according to standard procedures and is collected in plastic bags containing anti coagulant. MSCs are given via i.v. After huc-MSCs transfusion, patients are followed up once per week(in the first months,<1M),once per 2 week(1-3M)and once per month(3-6M), and the evaluation of liver function and biliary blood supply was performed."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Ischemic-type Biliary Lesions"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Liver transplantation",
          "Biliary complication",
          "mesenchymal stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2",
          "Phase 3"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Prevention",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "66",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Conventional treatment, huc-MSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: huc-MSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Conventional plus placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "huc-MSCs",
            "InterventionDescription": "Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional treatment, huc-MSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Umbilical Cord-Derived Mesenchymal Stem Cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional plus placebo"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "saline solution"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The incidence of ITBLs",
            "PrimaryOutcomeTimeFrame": "18 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes in biliary enzymology",
            "SecondaryOutcomeTimeFrame": "18 months"
          },
          {
            "SecondaryOutcomeMeasure": "Biliary blood supply",
            "SecondaryOutcomeDescription": "Biliary blood supply indicated by contrast-enhanced ultrasound.",
            "SecondaryOutcomeTimeFrame": "18 months"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "life quality",
            "OtherOutcomeTimeFrame": "18 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nbenign end-stage liver disease patients with liver transplantation.\nages of 18 and 60 years.\nfirst liver transplant.\ngamma-glutamyltransferase > 300 U/L for 2 weeks, and there was no or low enhancement of the wall of the hilar bile duct in arterial phase via contrast-enhanced ultrasonography.\nWritten informed consent.\n\nExclusion Criteria:\n\nsecond or combined organ transplant recipient.\nvital organs failure (Cardiac, Renal or Respiratory, et al).\nclinically active bacterial, fungal, viral or parasitic infection.\nother candidates who are judged to be not applicable to this study by investigators.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Yang yang, MD",
            "CentralContactRole": "Contact",
            "CentralContactEMail": "yysysu@163.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yang Yang, MD",
            "OverallOfficialAffiliation": "Third Affiliated Hospital, Sun Yat-Sen University",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Third Affiliated Hospital, Sun Yat-Sen University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationZip": "510630",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Yang Yang, PHD",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "yysysu@163.com"
                },
                {
                  "LocationContactName": "Yingcai Zhang",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "76207884@qq.com"
                },
                {
                  "LocationContactName": "Yang Yang, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemic",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          }
        ]
      }
    }
  }
}